Semaglutide al di là della diabete e dell'obesità: Revisione sistematica e meta-analisi dei benefici terapeutici multisistemi.

OBJECTIVES: To evaluate semaglutide's multisystem therapeutic benefits across 12 health domains. Primary outcomes were major adverse cardiovascular events, resolution of metabolic dysfunction-associated steatohepatitis, and composite renal endpoints. METHODS: PubMed, Embase, and Cochrane Central were searched through June 30, 2025, following Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines. Eligible studies included randomized controlled trials in adults (≥18 years) with ≥24-week follow-up comparing semaglutide (≥0.5 mg weekly subcutaneous or ≥7 mg daily oral) versus placebo or active comparators. Two reviewers independently extracted data and assessed bias